Inhibikase Therapeutics (IKT) Competitors $1.53 -0.07 (-4.38%) As of 10:17 AM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsSEC FilingsShort InterestTrendsBuy This Stock IKT vs. INBX, ATXS, CYRX, SLDB, ALMS, DRUG, LXEO, RAPT, AUTL, and CGEMShould you be buying Inhibikase Therapeutics stock or one of its competitors? The main competitors of Inhibikase Therapeutics include Inhibrx Biosciences (INBX), Astria Therapeutics (ATXS), CryoPort (CYRX), Solid Biosciences (SLDB), Alumis (ALMS), Bright Minds Biosciences (DRUG), Lexeo Therapeutics (LXEO), Rapt Therapeutics (RAPT), Autolus Therapeutics (AUTL), and Cullinan Therapeutics (CGEM). These companies are all part of the "pharmaceutical products" industry. Inhibikase Therapeutics vs. Its Competitors Inhibrx Biosciences Astria Therapeutics CryoPort Solid Biosciences Alumis Bright Minds Biosciences Lexeo Therapeutics Rapt Therapeutics Autolus Therapeutics Cullinan Therapeutics Inhibikase Therapeutics (NASDAQ:IKT) and Inhibrx Biosciences (NASDAQ:INBX) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, profitability, institutional ownership, risk, dividends and earnings. Do insiders and institutionals hold more shares of IKT or INBX? 3.8% of Inhibikase Therapeutics shares are owned by institutional investors. Comparatively, 82.5% of Inhibrx Biosciences shares are owned by institutional investors. 7.3% of Inhibikase Therapeutics shares are owned by company insiders. Comparatively, 17.1% of Inhibrx Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has more risk and volatility, IKT or INBX? Inhibikase Therapeutics has a beta of 0.89, indicating that its stock price is 11% less volatile than the S&P 500. Comparatively, Inhibrx Biosciences has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500. Does the media prefer IKT or INBX? In the previous week, Inhibrx Biosciences had 3 more articles in the media than Inhibikase Therapeutics. MarketBeat recorded 3 mentions for Inhibrx Biosciences and 0 mentions for Inhibikase Therapeutics. Inhibrx Biosciences' average media sentiment score of 0.48 beat Inhibikase Therapeutics' score of 0.30 indicating that Inhibrx Biosciences is being referred to more favorably in the news media. Company Overall Sentiment Inhibikase Therapeutics Neutral Inhibrx Biosciences Neutral Do analysts prefer IKT or INBX? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inhibikase Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Inhibrx Biosciences 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Which has stronger earnings and valuation, IKT or INBX? Inhibrx Biosciences has higher revenue and earnings than Inhibikase Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInhibikase Therapeutics$260K438.52-$27.52MN/AN/AInhibrx Biosciences$1.40M371.18$1.69B-$10.58-3.39 Is IKT or INBX more profitable? Inhibikase Therapeutics' return on equity of -63.82% beat Inhibrx Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Inhibikase TherapeuticsN/A -63.82% -58.03% Inhibrx Biosciences N/A -137.83%-76.31% SummaryInhibrx Biosciences beats Inhibikase Therapeutics on 7 of the 11 factors compared between the two stocks. Get Inhibikase Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for IKT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IKT vs. The Competition Export to ExcelMetricInhibikase TherapeuticsBiological Products, Except Diagnostic Substances IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$114.02M$307.50M$2.54B$10.57BDividend YieldN/AN/A2.51%4.78%P/E RatioN/AN/A26.0727.46Price / Sales438.52382.09116.44187.21Price / CashN/AN/A50.8761.86Price / Book1.123.3637.736.82Net Income-$27.52M-$111.70M$6.30M$276.90M7 Day Performance-7.83%-5.05%-0.04%0.55%1 Month Performance-1.92%2.45%1.17%7.90%1 Year PerformanceN/AN/A74.66%40.38% Inhibikase Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IKTInhibikase Therapeutics0.051 of 5 stars$1.53-4.4%N/AN/A$114.02M$260K0.006Gap UpINBXInhibrx Biosciences1.7077 of 5 stars$32.47-7.2%N/A+128.3%$470.17M$200K-3.07166High Trading VolumeATXSAstria Therapeutics2.0544 of 5 stars$8.31-1.7%$29.50+255.0%+3.7%$468.98MN/A-4.1330Trending NewsAnalyst DowngradeCYRXCryoPort3.6527 of 5 stars$9.30-6.4%$12.56+35.0%+35.5%$465.65M$228.38M6.991,186SLDBSolid Biosciences2.8007 of 5 stars$5.96-6.9%$15.00+151.7%-4.7%$464.10MN/A-2.13100ALMSAlumis3.5694 of 5 stars$4.44-2.0%$20.17+354.2%-56.7%$462.03MN/A0.00N/APositive NewsDRUGBright Minds Biosciences3.0108 of 5 stars$63.29+3.1%$81.00+28.0%+76.8%$445.56MN/A-68.05N/ANews CoveragePositive NewsAnalyst UpgradeLXEOLexeo Therapeutics2.7993 of 5 stars$8.24+0.5%$17.00+106.3%-1.1%$444.97MN/A-2.5358Analyst ForecastGap UpRAPTRapt Therapeutics3.3637 of 5 stars$26.79-10.7%$23.50-12.3%+86.7%$443.11M$1.53M-1.8980Analyst ForecastAnalyst RevisionAUTLAutolus Therapeutics3.4201 of 5 stars$1.66-5.7%$9.12+449.4%-59.6%$441.79M$29.93M-1.98330Gap UpCGEMCullinan Therapeutics3.2944 of 5 stars$7.40+5.0%$26.00+251.4%-46.9%$437.12MN/A-2.2930News CoveragePositive News Related Companies and Tools Related Companies Inhibrx Biosciences Competitors Astria Therapeutics Competitors CryoPort Competitors Solid Biosciences Competitors Alumis Competitors Bright Minds Biosciences Competitors Lexeo Therapeutics Competitors Rapt Therapeutics Competitors Autolus Therapeutics Competitors Cullinan Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IKT) was last updated on 10/16/2025 by MarketBeat.com Staff From Our PartnersBuilding The Infrastructure for the Coming Financial ResetWhile China pushes nearly $1 trillion through its new digital currency, one emerging company is quietly buildi...Intellistake | SponsoredOptions Pro Reveals His #1 Retirement Income TradeIf you can be at your computer between 9 a.m. and 10:45 a.m. on most weekdays, I’ll show you a simple trading ...Base Camp Trading | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredNvidia’s slow death marchEric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibikase Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inhibikase Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
